EV Biologics (EV Biologics) Inventories, Finished Goods : $0.03 Mil (As of Dec. 2017)

View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Inventories, Finished Goods?

EV Biologics's quarterly finished goods increased from Dec. 2016 ($0.04 Mil) to Jun. 2017 ($0.04 Mil) but then declined from Jun. 2017 ($0.04 Mil) to Dec. 2017 ($0.03 Mil).

EV Biologics's annual finished goods declined from Jun. 2015 ($0.09 Mil) to Jun. 2016 ($0.05 Mil) and declined from Jun. 2016 ($0.05 Mil) to Jun. 2017 ($0.04 Mil).

EV Biologics Inventories, Finished Goods Historical Data

The historical data trend for EV Biologics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Inventories, Finished Goods Chart

EV Biologics Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Inventories, Finished Goods

0.03

0.15

0.09

0.05

0.04

EV Biologics Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17	Dec17
Inventories, Finished Goods	Get a 7-Day Free Trial												0.05	0.07	0.04	0.04	0.03

EV Biologics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

EV Biologics (EV Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Inventories, Finished Goods

Comparable Companies

XCNQ:NIRV ENVB BLCM NLSP BRTX ADTX XKRX:066830 ALLR XMAD:ADL ARTL

Traded in Other Exchanges

N/A

Address

1621 Central Avenue, Cheyenne, WY, USA, 82001

Website

https://www.evbiologics.com

EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.

Executives

Daniel S Mckinney	director, 10 percent owner, officer: CEO	TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan	director	C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3